RENAGEL Side Effects

7020106-0 | Vomiting
on Sep 17, 2010 Male patient from UNITED STATES , weighting 220.5 lb, was diagnosed with hyperphosphataemia, hyperparathyroidism secondary and was treated with Renagel (View Usage). Patient experienced the following unwanted or unexpected effects: vomiting. Renagel dosage: 1.6 G, Tid. During the same period patient was treated with CINACALCET (30 Mg, Qd) (View Cinacalcet Review and Cinacalcet Label ), DOXERCALCIFEROL (1 Mcg, Tiw) (View Doxercalciferol Review and Doxercalciferol Label ). Patient was hospitalized.

7016033-5 | Diverticulum Intestinal Haemorrhagic
Patient was taking Renagel (View Usage). Patient had the following side effects: diverticulum intestinal haemorrhagic on Sep 15, 2010 from JAPAN Additional patient health information: Male patient , 69 years of age, was diagnosed with hyperphosphataemia and. Renagel dosage: Unk. Patient was hospitalized.

7014567-0 | Rhabdomyolysis
Adverse event was reported on Sep 14, 2010 by a Male patient taking Renagel (View Usage) (Dosage: .50 G, Tid) was diagnosed with hyperphosphataemia, hyperlipidaemia and. Location: JAPAN , weighting 134.5 lb, After Renagel was administered, patient had the following side effects: rhabdomyolysis. During the same period patient was treated with LIPITOR (5 Mg, Qd) (View Lipitor Review and Lipitor Label ), ASPIRIN (Unk) (View Aspirin Review and Aspirin Label ), PARIET (Unk) (View Pariet Review and Pariet Label ), FUROSEMIDE (Unk) (View Furosemide Review and Furosemide Label ), ALLEGRA (Unk) (View Allegra Review and Allegra Label ).

7006032-1 | Haemorrhagic Stroke
on Sep 10, 2010 Male patient from BRAZIL , weighting 120.2 lb, was diagnosed with hyperphosphataemia, fabry's disease and was treated with Renagel (View Usage). Patient experienced the following unwanted or unexpected effects: haemorrhagic stroke. Renagel dosage: Unk. During the same period patient was treated with FABRAZYME (70 Mg, Q2w) (View Fabrazyme Review and Fabrazyme Label ), RECOMBINANT ERYTHROPOIETIN (View Recombinant Erythropoietin Review and Recombinant Erythropoietin Label ), LOSARTAN POTASSIUM (View Losartan Potassium Review and Losartan Potassium Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), CARVEDILOL (View Carvedilol Review and Carvedilol Label ).


6992057-9 | Rhabdomyolysis
on Sep 07, 2010 Male patient from JAPAN , weighting 134.5 lb, was diagnosed with hyperphosphataemia, hyperlipidaemia and was treated with Renagel (View Usage). Patient had the following side effects: rhabdomyolysis. Renagel dosage: .50 G, Tid. During the same period patient was treated with LIPITOR (5 Mg, Qd) (View Lipitor Review and Lipitor Label ), ASPIRIN (Unk) (View Aspirin Review and Aspirin Label ), PARIET (Unk) (View Pariet Review and Pariet Label ), FUROSEMIDE (Unk) (View Furosemide Review and Furosemide Label ), ALLEGRA (Unk) (View Allegra Review and Allegra Label ).

6944835-X | Hospitalisation
Patient was taking Renagel (View Usage). After Renagel was administered, patient had the following side effects: hospitalisation on Aug 18, 2010 from UNITED STATES Additional patient health information: Female patient , 65 years of age, was diagnosed with hyperphosphataemia and. Renagel dosage: Unk. During the same period patient was treated with RENVELA (13.6 G, Qd) (View Renvela Review and Renvela Label ). Patient was hospitalized.

6943286-1 | Cellulitis, Gastrointestinal Hypomotility, Intestinal Obstruction
Adverse event was reported on Aug 18, 2010 by a Male patient taking Renagel (View Usage) (Dosage: 0.8 G, Tid) was diagnosed with hyperphosphataemia and. Location: UNITED KINGDOM , 79 years of age, Patient experienced the following unwanted or unexpected effects: cellulitis (What is cellulitis?), gastrointestinal hypomotility, intestinal obstruction. During the same period patient was treated with FUROSEMIDE (80 Mg, Bid) (View Furosemide Review and Furosemide Label ), IPRATROPIUM BROMIDE (500 Mcg, Unk) (View Ipratropium Bromide Review and Ipratropium Bromide Label ), LANSOPRAZOLE (15 Mg, Qd) (View Lansoprazole Review and Lansoprazole Label ), PREDNISOLONE (10 Mg, Qd) (View Prednisolone Review and Prednisolone Label ), ALBUTEROL SULFATE AUTOHALER (2.5 Mg, Qid) (View Albuterol Sulfate Autohaler Review and Albuterol Sulfate Autohaler Label ), SERETIDE (1 Df, Unk) (View Seretide Review and Seretide Label ), TAMSULOSIN HCL (400 Mg, Qd) (View Tamsulosin Hcl Review and Tamsulosin Hcl Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ). Patient was hospitalized and became disabled.

6931912-2 | Pancreatic Mass
on Aug 13, 2010 Male patient from CANADA , weighting 216.1 lb, was diagnosed with hyperphosphataemia and was treated with Renagel (View Usage). Patient had the following side effects: pancreatic mass. Renagel dosage: 8.8 G, Qd. During the same period patient was treated with ARANESP (View Aranesp Review and Aranesp Label ), DOCUSATE SODIUM (View Docusate Sodium Review and Docusate Sodium Label ), FERRLECIT (View Ferrlecit Review and Ferrlecit Label ), LACTULOSE (View Lactulose Review and Lactulose Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), QUINAPRIL (View Quinapril Review and Quinapril Label ), QUININE (View Quinine Review and Quinine Label ).

6925084-8 | Contusion, Haemoglobin Decreased, Rectal Haemorrhage, Urethral Haemorrhage, Vitamin K Decreased
on Aug 04, 2010 Male patient from NORWAY , weighting 154.3 lb, was diagnosed with hyperphosphataemia, depression (What is depression?), gout (What is gout?) and was treated with Renagel (View Usage). After Renagel was administered, patient had the following side effects: contusion, haemoglobin decreased, rectal haemorrhage, urethral haemorrhage, vitamin k decreased. Renagel dosage: 1.6 G, Tid. During the same period patient was treated with ZEMPLAR (2 Mcg, Qd) (View Zemplar Review and Zemplar Label ), CIPRAMIL (Unk) (View Cipramil Review and Cipramil Label ), TITRALAC (Unk) (View Titralac Review and Titralac Label ), NEXIUM (40 Mg, Qd) (View Nexium Review and Nexium Label ), AFIPRAN (10 Mg, Qd) (View Afipran Review and Afipran Label ), ATARAX (Unk) (View Atarax Review and Atarax Label ), ZYLORIC (100 Mg, Qd) (View Zyloric Review and Zyloric Label ), PREDNISOLONE (Unk) (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6856443-X | Alkalosis, Anaemia, Asthenia, Hypocalcaemia, Hypokalaemia, Laryngospasm, Metabolic Acidosis, Renal Impairment
Patient was taking Renagel (View Usage). Patient experienced the following unwanted or unexpected effects: alkalosis, anaemia, asthenia, hypocalcaemia, hypokalaemia, laryngospasm, metabolic acidosis, renal impairment on Jul 05, 2010 from RUSSIAN FEDERATION Additional patient health information: Male patient , weighting 17.20 lb, was diagnosed with hyperphosphataemia, anaemia and. Renagel dosage: 1/4 Tablet, Qid. During the same period patient was treated with KETOSTERIL (1 Tablet) (View Ketosteril Review and Ketosteril Label ), ALFACALCIDOL (4 Drops) (View Alfacalcidol Review and Alfacalcidol Label ), L CARNITINE (8 Drops, Tid) (View L-carnitine Review and L-carnitine Label ), MALTOFER (7 Drops) (View Maltofer Review and Maltofer Label ), RECORMON (Unk) (View Recormon Review and Recormon Label ), ARANESP (20 Mcg, 1x/w) (View Aranesp Review and Aranesp Label ). Patient was hospitalized.

6843388-4 | Contusion, Haemoglobin Decreased, Rectal Haemorrhage, Urethral Haemorrhage, Vitamin K Decreased
Adverse event was reported on Jul 02, 2010 by a Male patient taking Renagel (View Usage) (Dosage: 1.6 G, Tid) was diagnosed with hyperphosphataemia, depression (What is depression?), gout (What is gout?) and. Location: NORWAY , weighting 154.3 lb, Patient had the following side effects: contusion, haemoglobin decreased, rectal haemorrhage, urethral haemorrhage, vitamin k decreased. During the same period patient was treated with ZEMPLAR (2 Mcg, Qd) (View Zemplar Review and Zemplar Label ), CIPRAMIL (Unk) (View Cipramil Review and Cipramil Label ), TITRALAC (Unk) (View Titralac Review and Titralac Label ), NEXIUM (40 Mg, Qd) (View Nexium Review and Nexium Label ), AFIPRAN (10 Mg, Qd) (View Afipran Review and Afipran Label ), ATARAX (Unk) (View Atarax Review and Atarax Label ), ALLOPURINOL (100 Mg, Qd) (View Allopurinol Review and Allopurinol Label ), PREDNISOLON (Unk) (View Prednisolon Review and Prednisolon Label ). Patient was hospitalized.

6831763-3 | Constipation, Diarrhoea, Diverticulitis
on Jun 28, 2010 Male patient from JAPAN , 48 years of age, was diagnosed with hyperphosphataemia and was treated with Renagel (View Usage). After Renagel was administered, patient had the following side effects: constipation (What is constipation?), diarrhoea, diverticulitis. Renagel dosage: .

6810133-8 | Blood Bicarbonate Decreased, Diarrhoea, Metabolic Acidosis, Procedural Hypotension, Vomiting
on Jun 18, 2010 Male patient from ITALY , weighting 143.3 lb, was diagnosed with hyperphosphataemia and was treated with Renagel (View Usage). Patient experienced the following unwanted or unexpected effects: blood bicarbonate decreased, diarrhoea, metabolic acidosis, procedural hypotension, vomiting. Renagel dosage: 2.4 G, Qd. During the same period patient was treated with ALLOPURINOL (150 Mg, Unk) (View Allopurinol Review and Allopurinol Label ), LASIX (0.25 U, Unk) (View Lasix Review and Lasix Label ), ESOPRAL (1 U, Unk) (View Esopral Review and Esopral Label ), ASPIRIN (1 U, Unk) (View Aspirin Review and Aspirin Label ), ENAPREN (1 U, Unk) (View Enapren Review and Enapren Label ), NEORECORMON (1000 U, Unk) (View Neorecormon Review and Neorecormon Label ). Patient was hospitalized.

6784373-0 | Large Intestine Perforation, Multi-organ Failure, Pneumomediastinum, Subcutaneous Emphysema
Patient was taking Renagel (View Usage). Patient had the following side effects: large intestine perforation, multi-organ failure, pneumomediastinum, subcutaneous emphysema on Jun 09, 2010 from JAPAN Additional patient health information: Female patient , weighting 111.8 lb, was diagnosed with hyperphosphataemia, hyperparathyroidism secondary and. Renagel dosage: 0.5 G, Tid. During the same period patient was treated with REGPARA (25 Mg, Qd) (View Regpara Review and Regpara Label ), ALLOPURINOL (Unk) (View Allopurinol Review and Allopurinol Label ), LANSOPRAZOLE (Unk) (View Lansoprazole Review and Lansoprazole Label ), MYSLEE (Unk) (View Myslee Review and Myslee Label ), GASMOTIN (Unk) (View Gasmotin Review and Gasmotin Label ), NU LOTAN (Unk) (View Nu-lotan Review and Nu-lotan Label ), ALFAROL (Unk) (View Alfarol Review and Alfarol Label ), SODIUM PICOSULFATE (Unk) (View Sodium Picosulfate Review and Sodium Picosulfate Label ). Patient was hospitalized.

6781910-7 | Dyspnoea, Pulmonary Embolism
Adverse event was reported on Jun 11, 2010 by a Female patient taking Renagel (View Usage) (Dosage: 3.2 G, Qd) was diagnosed with hyperphosphataemia and. Location: GREECE , 42 years of age, weighting 172.0 lb, After Renagel was administered, patient had the following side effects: dyspnoea, pulmonary embolism (What is pulmonary embolism?). During the same period patient was treated with ISCOVER (75 Mg, Qd) (View Iscover Review and Iscover Label ), NEXIUM (40 Mg, Qd) (View Nexium Review and Nexium Label ), SOTALOL (160 Mg, Qd) (View Sotalol Review and Sotalol Label ), PLENDIL (10 Mg, Qd) (View Plendil Review and Plendil Label ), CELLCEPT (2 G, Qd) (View Cellcept Review and Cellcept Label ), LEVOTHYROXINE SODIUM (1 Mg, Qd) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), TOPAMAC (200 Mg, Qd) (View Topamac Review and Topamac Label ), ACTONEL (35 Mg, 1x/w) (View Actonel Review and Actonel Label ). Patient was hospitalized.

6771153-5 | Diarrhoea, Dysgeusia, Eating Disorder, Eructation, Nausea, Parosmia, Product Odour Abnormal
on Jun 14, 2010 Female patient from UNITED STATES , 56 years of age, weighting 112.4 lb, was diagnosed with blood phosphorus and was treated with Renagel (View Usage). Patient experienced the following unwanted or unexpected effects: diarrhoea, dysgeusia, eating disorder (What is eating disorder?), eructation, nausea (What is nausea?), parosmia, product odour abnormal. Renagel dosage: 4 Tab. 3 Times A Day.

6767877-6 | Large Intestine Perforation, Multi-organ Failure, Peritonitis, Pneumomediastinum, Subcutaneous Emphysema
on Jun 01, 2010 Female patient from JAPAN , weighting 111.8 lb, was diagnosed with hyperphosphataemia, hyperparathyroidism secondary and was treated with Renagel (View Usage). Patient had the following side effects: large intestine perforation, multi-organ failure, peritonitis, pneumomediastinum, subcutaneous emphysema. Renagel dosage: 0.5 G, Tid. During the same period patient was treated with REGPARA (25 Mg, Qd) (View Regpara Review and Regpara Label ), ALLOPURINOL (Unk) (View Allopurinol Review and Allopurinol Label ), LANSOPRAZOLE (Unk) (View Lansoprazole Review and Lansoprazole Label ), MYSLEE (Unk) (View Myslee Review and Myslee Label ), GASMOTIN (Unk) (View Gasmotin Review and Gasmotin Label ), NU LOTAN (Unk) (View Nu-lotan Review and Nu-lotan Label ), ALFAROL (Unk) (View Alfarol Review and Alfarol Label ), SODIUM PICOSULFATE (Unk) (View Sodium Picosulfate Review and Sodium Picosulfate Label ). Patient was hospitalized.

6763778-8 | Dyspnoea, Pulmonary Embolism
Patient was taking Renagel (View Usage). After Renagel was administered, patient had the following side effects: dyspnoea, pulmonary embolism (What is pulmonary embolism?) on May 31, 2010 from GREECE Additional patient health information: Female patient , 43 years of age, was diagnosed with hyperphosphataemia and. Renagel dosage: 0.8 G, Tid. During the same period patient was treated with PLAVIX (Unk) (View Plavix Review and Plavix Label ). Patient was hospitalized.

6755935-1 | Hospitalisation
Adverse event was reported on May 26, 2010 by a Male patient taking Renagel (View Usage) (Dosage: 1.6 G, Tid) was diagnosed with hyperphosphataemia and. Location: UNITED STATES , 82 years of age, Patient experienced the following unwanted or unexpected effects: hospitalisation. Patient was hospitalized.

6742310-9 | Azotaemia, Blood Thyroid Stimulating Hormone Increased, Thyroxine Decreased, Tri-iodothyronine Decreased
on May 10, 2010 Male patient from DENMARK , 70 years of age, was diagnosed with hyperphosphataemia, thyroidectomy and was treated with Renagel (View Usage). Patient had the following side effects: azotaemia, blood thyroid stimulating hormone increased, thyroxine decreased, tri-iodothyronine decreased. Renagel dosage: 0.8 G, Tid, Oral. During the same period patient was treated with LEVOTHYROXINE SODIUM (50 50 Mcg Per Day, Oral; 100 Mcg, Qd,; 50 Mcg, Qd,) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), OSVAREN (CALCIUM ACETATE AND MAGNESIUM CARBONATE) TABLET (435 Mg + 235 Mg, 1 Piece Tid, Oral) (View Osvaren (calcium Acetate And Magnesium Carbonate) Tablet Review and Osvaren (calcium Acetate And Magnesium Carbonate) Tablet Label ), PHOSPHATE BINDER (View Phosphate Binder Review and Phosphate Binder Label ).

6740519-1 | Blood Bicarbonate Decreased, Diarrhoea, Metabolic Acidosis, Procedural Hypotension, Vomiting
on May 17, 2010 Female patient from ITALY , weighting 143.3 lb, was diagnosed with hyperphosphataemia and was treated with Renagel (View Usage). After Renagel was administered, patient had the following side effects: blood bicarbonate decreased, diarrhoea, metabolic acidosis, procedural hypotension, vomiting. Renagel dosage: 2.4 G, Qd. During the same period patient was treated with ALLOPURINOL (150 Mg, Unk) (View Allopurinol Review and Allopurinol Label ), LASIX (0.25 U, Unk) (View Lasix Review and Lasix Label ), ESOPRAL (1 U, Unk) (View Esopral Review and Esopral Label ), ASPIRIN (1 U, Unk) (View Aspirin Review and Aspirin Label ), ENAPREN (1 U, Unk) (View Enapren Review and Enapren Label ), NEORECORMON (1000 U, Unk) (View Neorecormon Review and Neorecormon Label ). Patient was hospitalized.

6730609-1 | Contusion, Haemoglobin Decreased, Rectal Haemorrhage, Urethral Haemorrhage, Vitamin K Decreased
Patient was taking Renagel (View Usage). Patient experienced the following unwanted or unexpected effects: contusion, haemoglobin decreased, rectal haemorrhage, urethral haemorrhage, vitamin k decreased on May 07, 2010 from NORWAY Additional patient health information: Male patient , weighting 154.3 lb, was diagnosed with hyperphosphataemia, depression (What is depression?), gout (What is gout?) and. Renagel dosage: 1.6 G, Tid. During the same period patient was treated with ZEMPLAR (2 Mcg, Qd) (View Zemplar Review and Zemplar Label ), CIPRAMIL (Unk) (View Cipramil Review and Cipramil Label ), TITRALAC (Unk) (View Titralac Review and Titralac Label ), NEXIUM (40 Mg, Qd) (View Nexium Review and Nexium Label ), AFIPRAN (10 Mg, Qd) (View Afipran Review and Afipran Label ), ATARAX (Unk) (View Atarax Review and Atarax Label ), ZYLORIC (100 Mg, Qd) (View Zyloric Review and Zyloric Label ), PREDNISOLONE (Unk) (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6713689-9 | Contusion, Haemoglobin Decreased, Rectal Haemorrhage, Urethral Haemorrhage, Vitamin K Decreased
Adverse event was reported on Apr 27, 2010 by a Male patient taking Renagel (View Usage) (Dosage: 1.6 G, Tid) was diagnosed with hyperphosphataemia and. Location: NORWAY , weighting 154.3 lb, Patient had the following side effects: contusion, haemoglobin decreased, rectal haemorrhage, urethral haemorrhage, vitamin k decreased. During the same period patient was treated with ZEMPLAR (Unk) (View Zemplar Review and Zemplar Label ), CIPRAMIL (Unk) (View Cipramil Review and Cipramil Label ), TITRALAL (Unk) (View Titralal Review and Titralal Label ), NEXIUM (Unk) (View Nexium Review and Nexium Label ), AFIPRAN (Unk) (View Afipran Review and Afipran Label ), ATARAX (Unk) (View Atarax Review and Atarax Label ), ZYLORIC (Unk) (View Zyloric Review and Zyloric Label ), PREDNISOLON (Unk) (View Prednisolon Review and Prednisolon Label ). Patient was hospitalized.

6710262-3 | Abdominal Pain Upper, Acute Respiratory Failure, Asthenia, Burning Sensation, Chest Discomfort, Chest Pain, Chills, Diarrhoea, Dyspnoea
on Apr 21, 2010 Male patient from UNITED STATES , weighting 172.0 lb, was diagnosed with hyperphosphataemia, thrombosis prophylaxis and was treated with Renagel (View Usage). After Renagel was administered, patient had the following side effects: abdominal pain upper, acute respiratory failure, asthenia, burning sensation, chest discomfort, chest pain (What is chest pain?), chills, diarrhoea, dyspnoea. Renagel dosage: 1.6 G, Qd. During the same period patient was treated with HEPARIN SODIUM (Unk) (View Heparin Sodium Review and Heparin Sodium Label ), FOSRENOL (1 Tab) (View Fosrenol Review and Fosrenol Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), ALPHAGAN (View Alphagan Review and Alphagan Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), VITAMIN B COMPLEX CAP (View Vitamin B Complex Cap Review and Vitamin B Complex Cap Label ), CLOTRIMAZOLE (View Clotrimazole Review and Clotrimazole Label ). Patient was hospitalized.

6700604-7 | Oligohydramnios, Premature Labour
on Apr 12, 2010 Female patient from VENEZUELA , 40 years of age, weighting 127.9 lb, was diagnosed with hyperphosphataemia, hypertension and was treated with Renagel (View Usage). Patient experienced the following unwanted or unexpected effects: oligohydramnios, premature labour. Renagel dosage: 1.6 G, Tid, Oral; 0.8g Tid. During the same period patient was treated with ENALAPRIL MALEATE (20 Mg, Bid) (View Enalapril Maleate Review and Enalapril Maleate Label ), CAPTOPRIL (View Captopril Review and Captopril Label ), ROCALTROL (View Rocaltrol Review and Rocaltrol Label ), TITRALAC (AMINOACETIC ACID, CALCIUM CARBONATE) (View Titralac (aminoacetic Acid, Calcium Carbonate) Review and Titralac (aminoacetic Acid, Calcium Carbonate) Label ), ERITROPOYETINA (View Eritropoyetina Review and Eritropoyetina Label ), BENUTREX (ASCORBIC ACID, CALCIUM PANTOTHENATE, CYANOCOBALAMIN, NICOTIN (View Benutrex (ascorbic Acid, Calcium Pantothenate, Cyanocobalamin, Nicotin Review and Benutrex (ascorbic Acid, Calcium Pantothenate, Cyanocobalamin, Nicotin Label ), ACIDO FOLICO (FOLIC ACID) (View Acido Folico (folic Acid) Review and Acido Folico (folic Acid) Label ).

6700603-5 | Feeding Disorder Neonatal, Oropharyngeal Plaque, Premature Baby, Small For Dates Baby
Patient was taking Renagel (View Usage). Patient had the following side effects: feeding disorder neonatal, oropharyngeal plaque, premature baby, small for dates baby on Apr 12, 2010 from VENEZUELA Additional patient health information: Female patient , weighting 2.20 lb, was diagnosed with hyperphosphataemia, hypertension and. Renagel dosage: 1.6 G, Tid, Transplacental, 0.8 Gms Tid. During the same period patient was treated with ENALAPRIL MALEATE (20 Mg, Bid, Transplacental) (View Enalapril Maleate Review and Enalapril Maleate Label ), AMLODIPINE (AMLODIPINE MESILATE) (View Amlodipine (amlodipine Mesilate) Review and Amlodipine (amlodipine Mesilate) Label ), ROCALTROL (View Rocaltrol Review and Rocaltrol Label ), ERITROPOYETINA (View Eritropoyetina Review and Eritropoyetina Label ), BENUTREX (ASCORBIC ACID, CALCIUM PANTOTHENATE, CYANACOBALAMIN, NICOTIN (View Benutrex (ascorbic Acid, Calcium Pantothenate, Cyanacobalamin, Nicotin Review and Benutrex (ascorbic Acid, Calcium Pantothenate, Cyanacobalamin, Nicotin Label ), ACIDO FOLICO (FOLIC ACID) (View Acido Folico (folic Acid) Review and Acido Folico (folic Acid) Label ).

6692559-9 | Ecchymosis, Haemorrhage, Myocardial Infarction, Platelet Count Decreased
Adverse event was reported on Apr 05, 2010 by a Male patient taking Renagel (View Usage) (Dosage: 1.6 G, Bid, Oral ; 0.8 G, Bid,oral ; 1.6 G, Bid, Oral ; Oral) was diagnosed with hyperphosphataemia and. Location: BRAZIL , 80 years of age, After Renagel was administered, patient had the following side effects: ecchymosis, haemorrhage, myocardial infarction, platelet count decreased. During the same period patient was treated with PRE SATE (CHLORPHENTERMINE HYDROCHLORIDE) (View Pre-sate (chlorphentermine Hydrochloride) Review and Pre-sate (chlorphentermine Hydrochloride) Label ), ERYTHROPOIETIN (ERYTHROPOIETIN) (View Erythropoietin (erythropoietin) Review and Erythropoietin (erythropoietin) Label ), CALCIUM CARBONATE (View Calcium Carbonate Review and Calcium Carbonate Label ), FORASEQ (BUDESONIDE, FORMOTEROL) (View Foraseq (budesonide, Formoterol) Review and Foraseq (budesonide, Formoterol) Label ).

6668715-2 | Dysphagia, Dyspnoea, Eye Swelling, Lip Swelling, Local Swelling
on Mar 29, 2010 Male patient from SOUTH AFRICA , weighting 183.0 lb, was diagnosed with hyperphosphataemia, hypertension, gout (What is gout?), diabetes mellitus and was treated with Renagel (View Usage). Patient experienced the following unwanted or unexpected effects: dysphagia, dyspnoea, eye swelling, lip swelling, local swelling. Renagel dosage: 1.6 G, Tid. During the same period patient was treated with ATENOL (100 Mg, Qd) (View Atenol Review and Atenol Label ), PURISIS (Unk) (View Purisis Review and Purisis Label ), CARDURA (4.0 Mg, Qd) (View Cardura Review and Cardura Label ), ZANIDIP (10 Mg, Qd) (View Zanidip Review and Zanidip Label ), SIMVASTATIN (20 Mg, Qd) (View Simvastatin Review and Simvastatin Label ), PURICOS (100 Mg, Qd) (View Puricos Review and Puricos Label ), NOVOMIX (35 U, Qd) (View Novomix Review and Novomix Label ), ECTOTRIN (Unk) (View Ectotrin Review and Ectotrin Label ). Patient was hospitalized.

6665715-3 | Colitis, Colon Adenoma, Diarrhoea, Melanosis Coli
on Mar 24, 2010 Female patient from FRANCE , weighting 124.6 lb, was diagnosed with hyperphosphataemia, polyuria, hypocalcaemia and was treated with Renagel (View Usage). Patient had the following side effects: colitis, colon adenoma, diarrhoea, melanosis coli. Renagel dosage: 4.8 G, Qd. During the same period patient was treated with LASIX (500 Mg, Qd) (View Lasix Review and Lasix Label ), CALCIDIA (Unk) (View Calcidia Review and Calcidia Label ), IRON SULFATETHIAMIN COMPOUND TAB (1x/month) (View Iron Sulfatethiamin Compound Tab Review and Iron Sulfatethiamin Compound Tab Label ). Patient was hospitalized.

6664647-4 | Anaemia, Gastrointestinal Haemorrhage
Patient was taking Renagel (View Usage). After Renagel was administered, patient had the following side effects: anaemia, gastrointestinal haemorrhage on Mar 18, 2010 from JAPAN Additional patient health information: Male patient , 79 years of age, weighting 130.5 lb, was diagnosed with hyperphosphataemia and. Renagel dosage: 1.5 G, Tid, Oral. During the same period patient was treated with MUCOSTA (REBAMIPIDE) TABLET (View Mucosta (rebamipide) Tablet Review and Mucosta (rebamipide) Tablet Label ), CALTAN (CALCIUM CARBONATE) TABLET (View Caltan (calcium Carbonate) Tablet Review and Caltan (calcium Carbonate) Tablet Label ), ANZIEF (ALLOPURINOL) TABLET (View Anzief (allopurinol) Tablet Review and Anzief (allopurinol) Tablet Label ), ARGAMATE (CALCIUM POLYSTYRENE SULFONATE) (View Argamate (calcium Polystyrene Sulfonate) Review and Argamate (calcium Polystyrene Sulfonate) Label ), NORVASC (View Norvasc Review and Norvasc Label ). Patient was hospitalized.

6663713-7 | Osteonecrosis, Stress Fracture
Adverse event was reported on Mar 22, 2010 by a Male patient taking Renagel (View Usage) (Dosage: 6.4 G, Qd) was diagnosed with hyperphosphataemia, hyperparathyroidism secondary, hypercalcaemia and. Location: DENMARK , weighting 202.8 lb, Patient experienced the following unwanted or unexpected effects: osteonecrosis (What is osteonecrosis?), stress fracture. During the same period patient was treated with LANTHANUM CARBONATE (3 G, Qd) (View Lanthanum Carbonate Review and Lanthanum Carbonate Label ), CINACALCET HYDROCHLORIDE (30 Mg, Qd) (View Cinacalcet Hydrochloride Review and Cinacalcet Hydrochloride Label ), ARANESP (40 Mcg, 1x/w) (View Aranesp Review and Aranesp Label ), AMARYL (2 Mg, Qd) (View Amaryl Review and Amaryl Label ).

6657474-5 | Convulsion, Nausea
on Mar 19, 2010 Female patient from GERMANY , weighting 158.7 lb, was diagnosed with hyperphosphataemia and was treated with Renagel (View Usage). Patient had the following side effects: convulsion, nausea (What is nausea?). Renagel dosage: 1.6 G, Tid. During the same period patient was treated with KEPRA (View Kepra Review and Kepra Label ).

6626831-5 | Congenital Anomaly, Feeding Disorder Neonatal, Oropharyngeal Plaque, Premature Baby
on Feb 22, 2010 Female patient from VENEZUELA , weighting 2.20 lb, was diagnosed with hyperphosphataemia and was treated with Renagel (View Usage). After Renagel was administered, patient had the following side effects: congenital anomaly, feeding disorder neonatal, oropharyngeal plaque, premature baby. Renagel dosage: 1.6 G, Tid, Transplacental; 0.8 G, Tid,. During the same period patient was treated with ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ), AMLODIPINE (AMLODIPINE MESILATE) (View Amlodipine (amlodipine Mesilate) Review and Amlodipine (amlodipine Mesilate) Label ), ROCALTROL (View Rocaltrol Review and Rocaltrol Label ), ERITROPOYETINA (View Eritropoyetina Review and Eritropoyetina Label ), BENUTREX (ASCORBIC ACID, CALCIUM PANTOTHENATE, CYANOCOBALAMIN, NICOTIN (View Benutrex (ascorbic Acid, Calcium Pantothenate, Cyanocobalamin, Nicotin Review and Benutrex (ascorbic Acid, Calcium Pantothenate, Cyanocobalamin, Nicotin Label ), ACIDO FOLICO (FOLIC ACID) (View Acido Folico (folic Acid) Review and Acido Folico (folic Acid) Label ).

6626830-3 | Oligohydramnios, Premature Labour
Patient was taking Renagel (View Usage). Patient experienced the following unwanted or unexpected effects: oligohydramnios, premature labour on Feb 22, 2010 from VENEZUELA Additional patient health information: Female patient , 40 years of age, weighting 127.9 lb, was diagnosed with hyperphosphataemia and. Renagel dosage: 1.6 G, Tid, Oral; 0.8 G, Tid, Oral. During the same period patient was treated with CAPTOPRIL (View Captopril Review and Captopril Label ), ROCALTROL 9CALCITRIOL) (View Rocaltrol 9calcitriol) Review and Rocaltrol 9calcitriol) Label ), TITRALAC (AMINOACETIC ACID, CALCIUM CARBONATE) (View Titralac (aminoacetic Acid, Calcium Carbonate) Review and Titralac (aminoacetic Acid, Calcium Carbonate) Label ), ERITROPOYETINA (View Eritropoyetina Review and Eritropoyetina Label ), BENUTREX (ASCORBIC ACID, CALCIUM PANTOTHENATE, CYANOCOBALAMIN, NICOTIN (View Benutrex (ascorbic Acid, Calcium Pantothenate, Cyanocobalamin, Nicotin Review and Benutrex (ascorbic Acid, Calcium Pantothenate, Cyanocobalamin, Nicotin Label ), ACIDO FOLICO (FOLIC ACID) (View Acido Folico (folic Acid) Review and Acido Folico (folic Acid) Label ), ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ).

6623907-3 | Diverticulitis, Hyperphosphataemia
Adverse event was reported on Mar 03, 2010 by a Male patient taking Renagel (View Usage) (Dosage: Unk) was diagnosed with hyperphosphataemia and. Location: UNITED KINGDOM , 27 years of age, Patient had the following side effects: diverticulitis, hyperphosphataemia. During the same period patient was treated with FOSRENOL (1000 Mg, Tid) (View Fosrenol Review and Fosrenol Label ). Patient was hospitalized.

6616986-0 | Anaemia, Gastrointestinal Haemorrhage
on Feb 16, 2010 Male patient from JAPAN , 79 years of age, weighting 130.5 lb, was diagnosed with hyperphosphataemia, melaena and was treated with Renagel (View Usage). After Renagel was administered, patient had the following side effects: anaemia, gastrointestinal haemorrhage. Renagel dosage: 1.5 G, Tid, Oral. During the same period patient was treated with MUCOSTA (REBAMIPIDE) TABLET (View Mucosta (rebamipide) Tablet Review and Mucosta (rebamipide) Tablet Label ), CALTAN (CALCIUM CARBONATE) TABLET (View Caltan (calcium Carbonate) Tablet Review and Caltan (calcium Carbonate) Tablet Label ), ANZIEF (ALLOPURINOL) TABLET (View Anzief (allopurinol) Tablet Review and Anzief (allopurinol) Tablet Label ), ARGAMATE (CALCIUM POLYSTYRENE SULFONATE) (View Argamate (calcium Polystyrene Sulfonate) Review and Argamate (calcium Polystyrene Sulfonate) Label ), NORVASC (View Norvasc Review and Norvasc Label ). Patient was hospitalized.

6616941-0 | Congenital Cystic Kidney Disease, Insomnia, Keratosis Follicular, Oral Administration Complication, Renal Pain
on Feb 16, 2010 Female patient from UNITED STATES , 64 years of age, was diagnosed with hyperphosphataemia and was treated with Renagel (View Usage). Patient experienced the following unwanted or unexpected effects: congenital cystic kidney disease, insomnia, keratosis follicular, oral administration complication, renal pain. Renagel dosage: 1.6 G, Oral; 4 G, Tid, Oral. During the same period patient was treated with HYDROCODONE BITARTRATE (View Hydrocodone Bitartrate Review and Hydrocodone Bitartrate Label ), TOPROL XL (View Toprol-xl Review and Toprol-xl Label ), ALBUTEROL (SALBUTAMOL) INHALATION GAS (View Albuterol (salbutamol) Inhalation Gas Review and Albuterol (salbutamol) Inhalation Gas Label ). Patient was hospitalized.

6608175-0 | Blood Pressure Increased, Hospitalisation
Patient was taking Renagel (View Usage). Patient had the following side effects: blood pressure increased, hospitalisation on Feb 15, 2010 from GERMANY Additional patient health information: Female patient , child 5 years of age, was diagnosed with hyperphosphataemia, hypertension and. Renagel dosage: Unk. During the same period patient was treated with LORZAAR (Unk) (View Lorzaar Review and Lorzaar Label ). Patient was hospitalized.

6603652-0 | Anaemia, Diverticulum Intestinal Haemorrhagic, Gastrointestinal Haemorrhage
Adverse event was reported on Feb 03, 2010 by a Male patient taking Renagel (View Usage) (Dosage: 1.5 G, Tid, Oral) was diagnosed with melaena and. Location: JAPAN , 79 years of age, weighting 130.5 lb, After Renagel was administered, patient had the following side effects: anaemia, diverticulum intestinal haemorrhagic, gastrointestinal haemorrhage. During the same period patient was treated with MUCOSTA (REBAMIPIDE) TABLET (View Mucosta (rebamipide) Tablet Review and Mucosta (rebamipide) Tablet Label ), CALTAN (CALCIUM CARBONATE) TABLET (View Caltan (calcium Carbonate) Tablet Review and Caltan (calcium Carbonate) Tablet Label ), ANZIEF (ALLOPURINOL) TABLET (View Anzief (allopurinol) Tablet Review and Anzief (allopurinol) Tablet Label ), ARGAMATE (CALCIUM POLYSTYRENE SULFONATE) (View Argamate (calcium Polystyrene Sulfonate) Review and Argamate (calcium Polystyrene Sulfonate) Label ), NORVASC (View Norvasc Review and Norvasc Label ). Patient was hospitalized.

6596901-9 | Colitis, Colon Adenoma, Diarrhoea, Melanosis Coli
on Feb 11, 2010 Female patient from FRANCE , weighting 124.6 lb, was diagnosed with hyperphosphataemia, polyuria, hypocalcaemia and was treated with Renagel (View Usage). Patient experienced the following unwanted or unexpected effects: colitis, colon adenoma, diarrhoea, melanosis coli. Renagel dosage: 4.8 G, Qd. During the same period patient was treated with LASILIX (500 Mg, Qd) (View Lasilix Review and Lasilix Label ), CALCIDIA (Unk) (View Calcidia Review and Calcidia Label ), IRON SULFATETHIAMIN COMPOUND TAB (1x/month) (View Iron Sulfatethiamin Compound Tab Review and Iron Sulfatethiamin Compound Tab Label ). Patient was hospitalized.

6569266-6 | Abdominal Discomfort, Blood Urine Present, Feeling Abnormal, Hypophagia, Malaise, Product Odour Abnormal, Product Taste Abnormal
on Feb 01, 2010 Female patient from UNITED STATES , weighting 87.00 lb, was diagnosed with renal failure chronic and was treated with Renagel (View Usage). Patient had the following side effects: abdominal discomfort, blood urine present, feeling abnormal, hypophagia, malaise, product odour abnormal, product taste abnormal. Renagel dosage: 800 Mg 3 Times A Day.

6554182-6 | Choking, Congenital Cystic Kidney Disease, Insomnia, Oral Administration Complication, Pruritus, Renal Pain
Patient was taking Renagel (View Usage). After Renagel was administered, patient had the following side effects: choking (What is choking?), congenital cystic kidney disease, insomnia, oral administration complication, pruritus, renal pain on Jan 08, 2010 from UNITED STATES Additional patient health information: Female patient , 64 years of age, was diagnosed with hyperphosphataemia and. Renagel dosage: 4 G, Tid, Oral.

6551211-0 | Blister, Pruritus, Scar, Skin Disorder, Urticaria
Adverse event was reported on Jan 08, 2010 by a Female patient taking Renagel (View Usage) (Dosage: 2 Tab, Tid, Oral) was diagnosed with hyperphosphataemia and. Location: FRANCE , 50 years of age, weighting 116.8 lb, Patient experienced the following unwanted or unexpected effects: blister, pruritus, scar (What is scar?), skin disorder, urticaria. During the same period patient was treated with CINACALCET HYDROCHLORIDE (90 Mg, Qd,) (View Cinacalcet Hydrochloride Review and Cinacalcet Hydrochloride Label ).

6546816-7 | Condition Aggravated, Diabetes Mellitus, Impaired Gastric Emptying
on Jan 05, 2010 Male patient from UNITED STATES , 55 years of age, was diagnosed with hyperphosphataemia and was treated with Renagel (View Usage). Patient had the following side effects: condition aggravated, diabetes mellitus, impaired gastric emptying. Renagel dosage: 0.8 G, Tid, Oral. During the same period patient was treated with ARANESP (View Aranesp Review and Aranesp Label ), CLONDINE (CLONIDINE) (View Clondine (clonidine) Review and Clondine (clonidine) Label ), DIALYVITE (View Dialyvite Review and Dialyvite Label ), SS ASPART INSULIN (View Ss Aspart Insulin Review and Ss Aspart Insulin Label ), ISOSORBIDE (ISOSIRBIDE) (View Isosorbide (isosirbide) Review and Isosorbide (isosirbide) Label ), LANTUS (View Lantus Review and Lantus Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ). Patient was hospitalized.

6536827-X | Blood Thyroid Stimulating Hormone Increased, Thyroxine Decreased, Tri-iodothyronine Decreased
on Dec 21, 2009 Male patient from DENMARK , 70 years of age, was diagnosed with hyperphosphataemia, thyroidectomy, hyperkalaemia and was treated with Renagel (View Usage). After Renagel was administered, patient had the following side effects: blood thyroid stimulating hormone increased, thyroxine decreased, tri-iodothyronine decreased. Renagel dosage: Oral; 0.8 G, Tid, Oral. During the same period patient was treated with LEVOTHYROXINE SODIUM (50 50 Mcg Per Day, Oral) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), FOSRENOL (750 Mg, Tid, Oral) (View Fosrenol Review and Fosrenol Label ), VITAMIN B COMPLEX (VITAMIN B KOMPLEX STANDARD) (View Vitamin B Complex (vitamin-b-komplex Standard) Review and Vitamin B Complex (vitamin-b-komplex Standard) Label ), MICARDIS (View Micardis Review and Micardis Label ). Patient was hospitalized.

6532155-7 | Intestinal Obstruction
Patient was taking Renagel (View Usage). Patient experienced the following unwanted or unexpected effects: intestinal obstruction on Jan 28, 2009 from UNITED STATES Additional patient health information: Male patient , 51 years of age, was diagnosed with hyperphosphataemia and. Renagel dosage: 12.8 G, Qd, Oral. Patient was hospitalized.

6530391-7 | Hypokalaemia, Impaired Gastric Emptying, Vomiting
Adverse event was reported on Dec 21, 2009 by a Female patient taking Renagel (View Usage) (Dosage: Oral) was diagnosed with hyperphosphataemia and. Location: UNITED STATES , 30 years of age, Patient had the following side effects: hypokalaemia, impaired gastric emptying, vomiting. During the same period patient was treated with INSULIN (INSULIN) (View Insulin (insulin) Review and Insulin (insulin) Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), NEPHRO VITE (VITAMINS NOS) (View Nephro-vite (vitamins Nos) Review and Nephro-vite (vitamins Nos) Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), REGLAN (View Reglan Review and Reglan Label ), PROTONIX (View Protonix Review and Protonix Label ). Patient was hospitalized.

6525343-7 | Anaemia, Gastrointestinal Haemorrhage
on Dec 15, 2009 Male patient from JAPAN , 79 years of age, was diagnosed with hyperphosphataemia and was treated with Renagel (View Usage). After Renagel was administered, patient had the following side effects: anaemia, gastrointestinal haemorrhage. Renagel dosage: 1.5 G, Tid, Oral. During the same period patient was treated with ARGAMATE (CALCIUM POLYSTYRENE SULFONATE) (View Argamate (calcium Polystyrene Sulfonate) Review and Argamate (calcium Polystyrene Sulfonate) Label ), CALTAN (CALCIUM CARBONATE) (View Caltan (calcium Carbonate) Review and Caltan (calcium Carbonate) Label ). Patient was hospitalized.

6480483-6 | Oesophageal Stenosis
on Nov 19, 2009 Male patient from UNITED STATES , 41 years of age, was diagnosed with hyperphosphataemia and was treated with Renagel (View Usage). Patient experienced the following unwanted or unexpected effects: oesophageal stenosis. Renagel dosage: 1.6 G, Tid, Oral.

6467517-X | Arteriovenous Fistula Site Complication, Dementia, Hip Arthroplasty, Knee Arthroplasty, Oral Administration Complication
Patient was taking Renagel (View Usage). Patient had the following side effects: arteriovenous fistula site complication, dementia (What is dementia?), hip arthroplasty, knee arthroplasty, oral administration complication on Nov 16, 2009 from UNITED STATES Additional patient health information: Male patient , 74 years of age, was diagnosed with hyperphosphataemia and. Renagel dosage: Oral. Patient was hospitalized and became disabled.